Literature DB >> 11093725

Increased hepatic iron and cirrhosis: no evidence for an adverse effect on patient outcome following liver transplantation.

K A Stuart1, L M Fletcher, A D Clouston, S V Lynch, D M Purdie, P Kerlin, D H Crawford.   

Abstract

It has been suggested that preexisting severe hepatic iron overload may adversely affect outcome after liver transplantation. The pathogenesis of iron overload in cirrhosis in the absence of hemochromatosis gene (HFE) mutations is poorly understood. The relationships between liver disease severity and etiology, degree of hepatic iron overload, and post-liver transplantation outcome were studied in 282 consecutive adult patients with cirrhosis. Thirty-seven percent of patients had stainable hepatic iron. Increased hepatic iron concentration was significantly associated with more severe liver disease (P<.001), male sex (P = .05), the presence of spur cell anemia (P<.0001), and hepatocellular liver disease (P<.0001). The HFE mutations were uncommon in patients with increased hepatic iron stores. Increased hepatic iron concentration was not associated with greater utilization of resources or a lower survival after liver transplantation. Child-Pugh score at the time of liver transplantation was the only independent variable affecting patient survival (P = .0008). In summary, our data suggest that the severity of the liver disease rather than hepatic iron concentration is the most important determinant of outcome after liver transplantation and that, in general, increasing hepatic iron concentration in cirrhosis is a surrogate marker of the severity of the underlying liver disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11093725     DOI: 10.1053/jhep.2000.20348

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  5 in total

1.  The diagnosis and management of hereditary haemochromatosis.

Authors:  Paul Clark; Laurence J Britton; Lawrie W Powell
Journal:  Clin Biochem Rev       Date:  2010-02

2.  A Single Center Study Comparing the Stainable Iron Depositions in 1000 Explanted Cirrhotic Livers of Different Causes.

Authors:  Bita Geramizadeh; Yalda Ghazanfari; Saman Nikeghbalian; Seyed-Ali Malekhosseini
Journal:  Hepat Mon       Date:  2015-12-28       Impact factor: 0.660

3.  Combination curcumin and vitamin E treatment attenuates diet-induced steatosis in Hfe-/- mice.

Authors:  Mandy Heritage; Lesley Jaskowski; Kim Bridle; Catherine Campbell; David Briskey; Laurence Britton; Linda Fletcher; Luis Vitetta; V Nathan Subramaniam; Darrell Crawford
Journal:  World J Gastrointest Pathophysiol       Date:  2017-05-15

4.  Iron metabolism imbalance at the time of listing increases overall and infectious mortality after liver transplantation.

Authors:  Elodie Fallet; Michel Rayar; Amandine Landrieux; Christophe Camus; Pauline Houssel-Debry; Caroline Jezequel; Ludivine Legros; Thomas Uguen; Martine Ropert-Bouchet; Karim Boudjema; Dominique Guyader; Edouard Bardou-Jacquet
Journal:  World J Gastroenterol       Date:  2020-04-28       Impact factor: 5.742

5.  (+)-Clausenamide protects against drug-induced liver injury by inhibiting hepatocyte ferroptosis.

Authors:  Min Wang; Chun-Yu Liu; Tian Wang; Hong-Min Yu; Shu-Hua Ouyang; Yan-Ping Wu; Hai-Biao Gong; Xiao-Hui Ma; Gen-Long Jiao; Lei-Lei Fu; Qiong-Shi Wu; Hiroshi Kurihara; Yi-Fang Li; Tao Shen; Rong-Rong He
Journal:  Cell Death Dis       Date:  2020-09-19       Impact factor: 8.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.